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Background:MIF is a pro-inflammatory cytokine implicated in autoimmune diseases.
Results: A small molecule that binds to MIF and inhibits its cytokine activities was identified.
Conclusion: The inhibitor binds in a unique region on MIF and reveals a new way to block the cytokine activities of MIF.
Significance: The inhibitor is a valuable tool to design MIF-directed therapeutics for inflammatory diseases.
Macrophage migration inhibitory factor (MIF) is a catalytic
cytokine and an upstream mediator of the inflammatory path-
way. MIF has broad regulatory properties, dysregulation of
which has been implicated in the pathology of multiple immu-
nological diseases. Inhibition of MIF activity with small mole-
cules has proven beneficial in a number of disease models.
Known small molecule MIF inhibitors typically bind in the tau-
tomerase site of the MIF trimer, often covalently modifying the
catalytic proline. Allosteric MIF inhibitors, particularly those
that associate with the protein by noncovalent interactions,
could reveal novel ways to block MIF activity for therapeutic
benefit and serve as chemical probes to elucidate the structural
basis for the diverse regulatory properties of MIF. In this study,
we report the identification and functional characterization of a
novel allosteric MIF inhibitor. Identified from a high through-
put screening effort, this sulfonated azo compound termedp425
strongly inhibited the ability of MIF to tautomerize 4-hydroxy-
phenyl pyruvate. Furthermore, p425 blocked the interaction of
MIF with its receptor, CD74, and interfered with the pro-in-
flammatory activities of the cytokine. Structural studies
revealed a unique mode of binding for p425, with a single mol-
ecule of the inhibitor occupying the interface of two MIF trim-
ers. The inhibitor binds MIF mainly on the protein surface
through hydrophobic interactions that are stabilized by hydro-
gen bondingwith four highly specific residues from three differ-
ent monomers. The mode of p425 binding reveals a unique way
to block the activity of the cytokine for potential therapeutic
benefit in MIF-associated diseases.
Macrophage migration inhibitory factor (MIF)2 is a multi-
functional protein that is both a cytokine and an enzyme pos-
sessing tautomerase activity (1). In the capacity of a cytokine,
MIF functions as a central upstreammediator of innate immu-
nity and a regulator of inflammation (2). MIF is believed to
initiate inflammation by promoting the release of pro-inflam-
matorymediators, such as TNF, interleukins (IL-1, IL-6, and
IL-8), and tissue-degradingmatrix metalloproteinases (MMPs)
(3–5). MIF also promotes inflammation by inducing a wide
range of pro-inflammatory cellular processes, which include
phagocytosis, T-cell proliferation, counter-regulation of
immunosuppressive action of glucocorticoids, activation of
macrophages, and promotion of their continued survival
through suppression of p53-dependent apoptosis (2, 6–11).
Although the molecular mechanism underlying the pleiotropic
functions of MIF remains unresolved, it is known that MIF
exerts at least part of its cytokine activity through signal trans-
duction, initiated by direct binding to the CD74-CD44 extra-
cellular receptor complex (12–14).
Given the broad immunomodulatory properties ofMIF, dys-
regulation of its function has been implicated in the pathophys-
iology of a variety of diseases. Elevated circulating levels of MIF
have been observed in rheumatoid arthritis, atherosclerosis,
asthma, lupus, diabetes, colitis, sepsis, cancer, and cardiovascu-
lar and infectious diseases (15–20). Genetic evidence further
supports the involvement of MIF in disease. Functional poly-
morphisms in the MIF gene affect disease severity, such that
individuals inheriting a high expressor allele have increased lev-
els of MIF in circulation and often show severe disease mani-
festation. Therapeutic relief achieved through blocking MIF
activity by genetic, immunological, and pharmacologicalmeans
further supports the involvement of MIF in disease pathology
(17, 21–24).* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grant 1R43AR056908 from the NIAMS.
Theatomic coordinatesandstructure factors (code3U18)havebeendeposited in
the Protein Data Bank, Research Collaboratory for Structural Bioinformatics,
Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
1 Towhomcorrespondence shouldbe addressed: L2Diagnostics, 300George
St., Ste. 309, New Haven, CT 06511. Tel.: 203-503-0383; Fax: 203-503-0384;
E-mail: Karen.Anthony@L2dx.com.
2 The abbreviations used are: MIF, macrophage migration inhibitory factor;
HTS, high throughput screen; HPP, 4-hydroxyphenyl pyruvate; rhMIF,
recombinant humanMIF; PDB, Protein Data Bank; TPOR, thiol-protein oxi-
doreductase; MMP, matrix metalloproteinase.
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In addition to its physiological and pathophysiological activ-
ities, MIF is known to act as a tautomerase capable of isomer-
izing substrates such as D-dopachrome and 4-hydroxyphenyl
pyruvate (HPP) (26–28). No definite physiological role has
been assigned to the catalytic activity of MIF, which is thought
to be a vestige of its ancestral origin from bacterial isomerases
involved in aromatic amino acid catabolism (25). Nevertheless,
the uniqueness of an enzymatic activity associated with a cyto-
kine led to studies elucidating the structure-activity relation-
ship between the two activities. These studies revealed that in
vitro, MIF exists as a 37.5-kDa homotrimer (26, 27). The three
monomers that form the trimer exist as a -- structure com-
posed of two anti-parallel -helices packed against a four-
stranded -sheet. The subunits interact via intersubunit
-sheet contacts to form a symmetrical -barrel trimer with a
solvent-exposed central channel. At the monomer interface
within the trimer are three tautomerase active sites where the
N-terminal catalytic proline (Pro1) resides. The region encom-
passing the tautomerization site also makes critical contacts
with the CD74 receptor, such that covalent modification of
Pro1 or its replacement with glycine abolishes tautomerase
activity and impairs CD74 binding (12, 28–30).
Given the spatial relationship between the catalytic and
receptor binding domains, targeting the tautomerase activity of
MIF as a means to block its pro-inflammatory function has
been extensively explored as a therapeutic strategy. To date,
methods such as substrate analog screening, active-site target-
ing by computer-assisted modeling, and virtual high through-
put screening have produced various classes of small molecule
MIF tautomerase inhibitors (31). Themajority of the inhibitors,
which include derivatives of dopachrome, acetaminophen
(N-acetyl-p-benzoquinone), phenylpyruvic acid (cinnamates),
Schiff bases, isoxazolines (ISO-1), and isothiocyanates, act by
either competing with the substrate for the catalytic site (ISO-1
and OXIMM11) or covalent modification of Pro1 (N-acetyl-p-
benzoquinone and isothiocyanates) (28, 29, 32). Many of these
inhibitors have also been shown to inhibit the pro-inflamma-
tory activities ofMIF. For instance, ISO-1 and some of its deriv-
atives block MIF-induced TNF secretion from LPS-stimulated
macrophages and increase survival in a sepsis model (33, 34).
Although these inhibitors provide a proof of concept for the
therapeutic utility of small molecule MIF inhibitors, they are
not ideal for pharmaceutical development. ISO-1 for instance
was developed from a class of platelet glycoprotein IIb/IIIa
antagonists (35) and displays only micromolar potency with
respect to MIF inhibition (33, 36); its further development
raises significant concerns about low potency and off-target
effects. Covalent modifiers such as N-acetyl-p-benzoquinone
are not desirable as pharmaceuticals due to lack of specificity
(29, 37, 38).
Recently, the identification of two new classes of MIF inhib-
itors revealed the feasibility of blockingMIF tautomerase activ-
ity by mechanisms other than active-site binding. An analog of
the anti-inflammatory drug ibudilast binds to a region proximal
to the catalytic site, whereas the anti-oxidant ebselen disaggre-
gates MIF trimers (39, 40). Encouraged by these findings, we
sought to obtain additional allosteric MIF inhibitors that nei-
ther compete for nor covalently modify the active site. We
hypothesized that such inhibitors could not only block the tau-
tomerase activity of MIF but also block its pro-inflammatory
function. Herein, we report the identification, by high through-
put screening, of an azo compound named p425 that blocks the
tautomerase, CD74 receptor-binding, and pro-inflammatory
activities of MIF. Through crystallographic studies, we show
that the site of p425 binding to be at the interface of two MIF
trimers. With a mode of binding unique among known MIF
inhibitors, p425 reveals a new way to block the catalytic and
cytokine activities of MIF. This molecule could prove invalu-
able as a tool to designnewclasses of therapeuticMIF inhibitors
and to investigate the structural basis for the multifunctional
nature of MIF.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Recombinant
Human MIF (rhMIF)—The human MIF gene (GenBankTM
accession number BU538576.1) was PCR-amplified from an
EST cDNA clone purchased fromOpen Biosystems (Lafayette,
CO) using primers (5-CCCTCTAGAAATAATTTTGTTTA-
ACTTTAAGAAGGAGATATACAATGCCGATGTTCATC-
GTAAACACC-3 and 5-CCCAGATCTTATTAGGCGAAG-
GTGGAGTTGTTCCAG-3) and inserted into the XbaI/BglII
sites of pET32a vector (Novagen, Madison, WI). For protein
production, Escherichia coli BL21-DE3 (New England Biolabs,
Ipswich, MA) was transformed with the plasmid, grown in the
presence of isopropyl 1-thio--D-galactopyranoside (0.1 mM),
and harvested by sonication in 50mMMES, pH 6.1. The cleared
cell lysates were subjected to cation-exchange chromatography
on an SP-Sepharose XL column (GE Healthcare). MIF was fur-
ther purified by high resolution cation-exchange chromatogra-
phy in 50 mM MES, pH 6.1, on a Mono S 5/50 GL column (GE
Healthcare) under nondenaturing conditions. The composi-
tion of each fraction was determined by SDS-gel electrophore-
sis, and theMIF-containing fractions were dialyzed against 100
mM sodium citrate buffer, pH 5.0. The final yield was 20–25mg
of purified protein per liter of culture, with a purity of greater
than 99%.
Compound Libraries and High Throughput Screen (HTS)—
HTSwas performed at the Institute of Chemistry and Cell Biol-
ogy Longwood Screening Facility at Harvard Medical School.
The libraries consisted of 230,000 small molecules, which
included therapeutic compounds approved by the Food and
Drug Administration and compounds purchased from the fol-
lowing: BioMol TimTec (Plymouth Meeting, PA); Prestwick
(Ilkirch, France); ChemBridge (San Diego); ENAMINE (Kiev,
Ukraine); Maybridge (Cornwall, UK); ChemDiv (San Diego);
NINDS custom collection fromMicroSource Diversity System
(Gaylordsville, CT); and collections from the NCI, National
Institutes of Health, and Harvard Medical School. The HTS
assay was based on the keto-enol tautomerization of HPP
(Sigma) catalyzed by rhMIF (12). The keto form of HPP was
prepared by dissolving the HPP powder in 50 mM ammonium
acetate, pH 6.0, and equilibrating it overnight at room temper-
ature. For HTS, the assay was optimized in 384-well UVmicro-
plates from Corning (Corning, NY). A reaction mixture con-
taining 0.37M boric acid, pH 5.5, 78 nM rhMIF, and 8.9%DMSO
in water was prepared, and 30 l of this mixture was added to
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each well of a reaction plate. Test compounds (12 g/ml) were
added to the wells, and the mixture was preincubated for 30
min. A substrate mixture containing 0.34 M boric acid and 1.5
mM keto-HPP was prepared, and 10 l of this mixture was
added to each well of the reaction plate. A306 was read after a
15-min incubation on a SpectraMax M5 plate reader (Sunny-
vale, CA). The overall Z factor, a statistical measure of the
effective separation of the high and low controls, for the screen
was0.7, a value suitable for HTS (41). Hits were classified as
test compounds that inhibited the signal by50% as compared
with a no-inhibitor control.
Source of p425—For follow-up studies, p425 also known as
Chicago Sky Blue 6B was purchased from Tocris Biosciences
(catalog no. 0846, Bristol, UK).
MIF-CD74 Binding Assay—TheMIF-CD74 receptor binding
assay was performed as described previously (42, 43). Briefly,
recombinant human sCD74(73–232) (recombinant soluble
ectodomain of the receptor expressed and purified as described
previously (43)) was immobilized in 96-well plates overnight at
4 °C. After washing, the plates were blocked with Superblock
T20 (Thermo Scientific, Waltham, MA) for 2 h at room tem-
perature. Biotin-labeled rhMIF (0.2M) was preincubated with
either compounds or anti-humanMIF antibody (R&DSystems,
Goodhue, MN) for 30 min at room temperature. The mixture
was added to plates and incubated overnight at 4 °C.An alkaline
phosphatase-streptavidin conjugate (R&D Systems) and p-ni-
trophenyl phosphate substrate (Sigma)were added to eachwell,
and A405 was read in a plate reader (BioTek, Winooski, VT).
Percent inhibition at each inhibitor concentration was calcu-
lated with respect to a no-inhibitor control. The results were
fitted onto a sigmoidal dose-response curve using GraphPad
Prism 4.0 software (La Jolla, CA) to calculate the IC50 value
(compound concentration that causes 50% inhibition).
Cytokine Luminex Assay and ELISA—Human foreskin fibro-
blasts (CRL-2522, ATCC,Manassas, VA)were cultured inmin-
imum Eagle’ medium with 0.5% FBS (Invitrogen). Approxi-
mately 1  104 cells/well were plated in 96-well plates and
incubated overnight. The next day, 2.5 M of each test com-
pound was mixed with 200 ng/ml rhMIF in fresh culture
medium and incubated for 30 min at room temperature. This
mixture was added to cells, replacing the oldmedium. Controls
included ISO-1, anti-MIF antibody, and compound vehicle (1%
DMSO). After 6 h, the plates were centrifuged for 5 min at
200 g. Culture supernatant was collected, and the amount of
IL-6 and IL-8 in the medium was measured with a Bio-Plex kit
(Bio-Rad) in a Luminex 200 system (Bio-Rad). To confirm the
Bio-Plex results, test compounds (5-fold serially diluted for
final concentrations of 2.5 M to 0.4 nM) were incubated with
rhMIF and fibroblast cells for 6 h as above. Cell culture media
were collected and analyzed for individual cytokine production
with ELISA kits (R&D Systems), and IC50 values were
calculated.
MMP-3 ELISA—MMP-3 measurements were performed in
primary human synovial fibroblasts-rheumatoid arthritis (Cell
Applications, Inc., San Diego) using assay conditions similar to
those used for cytokine measurements. Approximately 1 104
cells/well were plated in a 96-well plate overnight and then
incubatedwith rhMIF 200 ng/ml either alone ormixedwith the
inhibitors (5-fold dilutions from 2.5M to 0.4 nM) for 24 h prior
to the analysis. MMP-3 levels in the medium were measured
with an ELISA kit (R&D Systems).
Apoptosis Assay—Apoptosis was measured in HeLa cells
(CCL-2, ATCC). Briefly, 1  104 cells in DMEM containing
0.5% FBS were plated into each well of a 96-well plate and incu-
bated overnight. To induce apoptosis, 1 g/ml camptothecin
(Sigma)was added to eachwell immediately followed by serially
diluted rhMIF/inhibitor mixture (200 ng/ml MIF). The cells
were incubated at 37 °C for 4 h. Apoptosis was measured with
the Cell Death Detection ELISAplus kit (Roche Applied Sci-
ence), which is a photometric enzyme immunoassay for the
quantitative in vitro determination of cytoplasmic histone-as-
sociated DNA fragments by induced cell death.
Cytotoxicity Assay—Compound-induced cytotoxicity was
measured in human foreskin fibroblast cells. Briefly, 1  104
cells/well, grown in MEM containing 10% FBS, were plated in
96-well plates. Serially diluted compounds were added to each
well, and the plates were incubated at 37 °C for 24 and 72 h. The
level of compound-induced cytotoxicity was determined using
a kit (Roche Applied Science) that measures the amount of lac-
tate dehydrogenase released into the medium by lysed cells rel-
ative to an untreated control.
Crystallization, Structure Determination, and Refinement—
Crystals of rhMIF-p425 complex were grown at 37 °C by vapor
diffusion in sitting drops after mixing equal volumes of protein
with precipitant solution. The protein solution consisted of 8
mg/ml rhMIF in 10 mM Tris, pH 7.2, and the precipitant solu-
tion consisted of a mixture of 100 mM p425 dissolved in 2.0 M
ammonium sulfate, 4% 2-propanol, 0.1 M Tris, pH 8.0. The sit-
ting drop was equilibrated against 0.5 ml of precipitant buffer
without p425, in 24-well VDXplates (Hampton Research, Aliso
Viejo, CA). Crystals grewwithin 2weeks; theywere dark blue in
color andwere of dimensions 0.5mmon the largest face and 0.3
mm on the smallest face. Single crystals were soaked in cryo-
protectant solution containing 15% ethylene glycol and 20%
glycerol in precipitant solution for less than 5 min and directly
cooled in a stream of liquid nitrogen prior to data collection.
Data were collected using a 4-circle  platform Xcalibur PX
Ultra with a 165-mm diagonal Onyx CCD detector and a high
brilliance sealed tube Enhance Ultra (copper) x-ray source
(Oxford Diffraction, Oxford, UK), operating at 40 kV and 40
mA at a crystal-to-detector distance of 65 mm and exposure
times of 120 s per 0.4° oscillations. The data sets were processed
using the programCrysalis Pro (Oxford Diffraction). Crystallo-
graphic phases were determined by molecular replacement
using the program PHASER (44). The search model used was
the coordinates of MIF (PDB code 1MIF (26)) stripped of all
heteroatoms. The initialMR solution revealed threemonomers
per asymmetric unit which, based on the volume of the unit cell
being 398946Å3, corresponds to aMatthews’ coefficient of 3.93
Å3 Da1 (68.7% solvent). MR was followed by several cycles of
simulated annealing at 10,000 K to remove model bias. The
ligand p425 was visible in the resulting unbiased Sigma
weighted 2Fo  Fc omit electron density maps. The structural
model was manually built using COOT (45) followed by refine-
ment using both PHENIX (46) and REFMAC5 (47) with free-R
(48) to yield a final model with statistics listed in Table 1. The
Allosteric Inhibition ofMIF
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coordinates corresponding to the different crystal structures
were superposed using a least square alignment of all main
chain atoms within PyMOL.
Protein Data Base Accession Number—The atomic coordi-
nates and structure factors of the p425-rhMIF complex are
available from the Protein Data Bank (PDB code 3U18).
RESULTS
Identification of p425 as an Inhibitor of MIF Tautomerase
and CD74 Receptor Binding Activities—rhMIF catalyzes the
keto-enol tautomerization of HPP, a reaction that can be mon-
itored spectrophotometrically as an increase in A306 (Fig. 1, A
andB).We developed a 384-well plate formatHPP tautomerase
assay and screened 230,000 compounds for inhibitors of rhMIF
HPP tautomerization. We identified 2,430 hits (1% hit rate),
which inhibited the tautomerase activity of rhMIF by greater
than 50% at 12g/ml (Fig. 1,C andD). The hit compoundswere
purchased and re-tested in the tautomerase assay, and 274 hits
were shown to have confirmed activity.
Because our goal was to obtain MIF tautomerase inhibitors
that also block its pro-inflammatory function, we proceeded to
test the 274 confirmed hits in a CD74 receptor-binding assay to
assess their ability to block theMIF-CD74 interaction. The abil-
ity of the hits to block the binding of biotinylated rhMIF with
recombinant soluble CD74 ectodomain (CD74(73–232)) was
evaluated in a capture ELISA (42, 43). Of the 274 hits evaluated,
four hits (p425, 1D2, 1H2, and 2F10) were inhibitory in the
receptor-binding assay (Fig. 2A). The most potent of the four
hits was p425, which displayed a dose-dependent inhibition
with an IC50 of 0.81 M. The structure of p425 is shown in Fig.
2B. It belongs to the azo family of large sulfonated organic acids
that include Evans blue, furosemide, and bumetanide, all of
which, at physiological pH, contain two centers of negative
charge in close proximity to an electron-donating group (49,
TABLE 1
Data collection andmodel refinement statistics
Values in parenthesis are for highest resolution shell.
Parameter MIF-P425 complex basic
Data collection
Space group P212121
Unit-cell parameters a 67.83, b 67.88, c 86.63 Å
Resolution limits (Å) 30.35 to 1.73 Å (1.82 to 1.73 Å)
I/(I) 12.7 (1.5)
No. of reflections 163,225 (2,859)
No. of unique reflections 37,365 (2,354)
Multiplicity 4.3 (1.2)
Rmergea 7.1% (35.2%)
Completeness 89.3% (39.4%)
Refinement
Resolution 30–1.8 (1.85–1.80)
Completeness (%) 95.95 (61.53)
Rcrystb/Rfreec 15.4/19.4 (22.5/27.1)
Correlation coefficient
Fo Fc 0.965
Fo Fc (free) 0.942
Root mean square deviation
Bond lengths 0.023 Å
Bond angles 2.211°
Model composition
Monomers 3
Residues 114
Waters 314
Ligands/heteroatoms
P425 (code Y0X) 1
Glycerol 9
Ethylene glycol 2
Isopropyl alcohol 2
Sulfate ions 2
Sodium 4
Ramachandran
Preferred regions 100%
Outliers 0%
aRmerge Shkl SiIi(hkl) (I(hkl))/Shkl Si Ii(hkl), where Ii(hkl) and (I(hkl)) are the
intensity of measurement of I and the mean intensity of the reflection with indi-
ces hkl, respectively.
b Rcryst SFo Fc/SFo, where Fo is the observed and Fc is the calculated struc-
ture factor amplitudes.
c Rfree set uses 5% of randomly chosen reflections.
FIGURE 1.High throughput screening for rhMIF HPP tautomerase inhibi-
tors. A, keto-enol tautomerization of HPP catalyzed by rhMIF. B, spectropho-
tometric detection of rhMIF-catalyzed HPP tautomerase reaction in a 384-
well plate format. C, scatter plot of HTS outcome for one of the two replicates
of 230,000 compounds. Compounds giving50% inhibition above the line
were classified as hits. D, distribution of the 2,430 hits, categorized into five
groups with respect to percent inhibition.
Allosteric Inhibition ofMIF
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50). Structure-based calculated properties of p425, including
the size (Mr 904) and four highly polar sulfonic acid moieties,
suggested that this molecule was unlikely to be an active-site
binder. Anticipating that p425 might be a novel MIF inhibitor,
we proceeded to examine this molecule in cell-based assays
evaluating the pro-inflammatory activities of MIF and in struc-
tural studies elucidating the physical nature of inhibitor-MIF
interactions.
p425 Impairs Pro-inflammatory Activities of MIF—We
selected three MIF-driven cellular events that are hallmarks of
inflammation to examine the inhibitory effects of p425 on the
pro-inflammatory action of MIF. It is known that during
inflammation, MIF promotes the following: (i) production of
IL-6 and IL-8 inflammatory mediators (5, 51–53); (ii) secretion
of MMPs (3, 4, 54, 55); and (iii) survival of cells through sup-
pression of p53-dependent apoptosis (7, 10). We evaluated the
ability of p425 to inhibit MIF activity in all three processes, and
we compared its activity to the prototypical MIF inhibitor
ISO-1.
It has been shown that pretreatment of fibroblasts with
rhMIF increases IL-6 and IL-8 cytokine levels in the culture
medium, and the presence of MIF-specific inhibitors, such as
ISO-1 and anti-MIF antibody, diminishes this effect (5). To
examine the effect of p425 on MIF-induced cytokine produc-
tion, we measured the levels of IL-6 and IL-8 in the culture
medium of human foreskin fibroblast cells, previously treated
with rhMIF in the presence or absence of p425, ISO-1, or anti-
MIF antibody. As shown in Fig. 3A, pretreatment of rhMIFwith
p425 causes a dramatic decrease in the cytokine levels, compa-
rable with that observed for anti-MIF antibody, and it wasmore
inhibitory than ISO-1. Fig. 3, B and C, shows the dose-depen-
dent nature of the response and the higher potency of p425 in
comparison with ISO-1 (IC50 of 0.6–0.7 M versus 5 M,
respectively).
We proceeded to examine the effect of p425 onMIF-induced
production of MMPs. MIF induces the expression of a number
of MMPs (3, 4, 54, 55), which with their unique ability to
degrade fibrillar collagens and other matrix components have
been implicated in the pathology of rheumatoid arthritis (56,
57). Primary human synovial fibroblasts were pretreated with
rhMIF alone or rhMIF in complexwith p425 or ISO-1. The level
of MMP-3 in the culture medium was measured, and the per-
cent inhibition with respect to a no-inhibitor control is pre-
sented in Fig. 3D. The results show that p425 decreased the
level of MMP-3 in the medium in a dose-dependent manner
with an IC50 of0.1 M. A similar, but less pronounced, effect
was seen with ISO-1, which had an IC50 of10 M.
Next, we examined the effect of p425 on apoptosis, a nor-
mal cellular process that serves to limit activation of inflam-
matory cells to prevent excessive inflammation. MIF over-
rides this checkpoint and promotes cell survival by
suppressing p53-dependent apoptosis (36). The effect of
MIF inhibitors on apoptosis can be assessed following treat-
ment of cells with camptothecin, a DNA-damaging agent
that promotes cell death through p53-dependent pathways.
HeLa cells were pretreated with camptothecin, followed by
treatment with rhMIF either alone or complexed with p425
or ISO-1. The results, summarized in Fig. 3E, reveal that
rhMIF dramatically reduces the extent of camptothecin-in-
duced apoptosis and that this effect is impaired, albeit mod-
estly, in the presence of 50 M p425. No discernible differ-
ence in the extent of apoptosis was seen in the presence of 2,
10, or 50 M of ISO-1 (data not shown).
We proceeded to examine toxicity of p425 on cells to
ensure that the inhibitory effects observed on the pro-in-
flammatory activities of rhMIF are not due to inhibitor-in-
duced cellular toxicity. Primary human foreskin fibroblasts
were treated with varying concentrations of p425 for 24 and
72 h, and the extent of cytotoxicity, as measured by the levels
of lactate dehydrogenase in the medium, was determined. As
shown in Fig. 3F, 100 M of p425 causes little or no cytotox-
icity. Collectively, these results confirm that p425 not only
inhibits the tautomerase and receptor binding activities of
MIF, but also impairs the ability of MIF to mediate produc-
tion of pro-inflammatory mediators and inhibit p53-depen-
dent apoptosis.
Structure of rhMIF-p425 Complex Reveals a Novel Mode of
MIF Inhibition—To understand themechanism by which p425
interacts with rhMIF, we solved the co-crystal structures of the
inhibitor-bound complex to 1.9-Å resolution. Co-crystalliza-
tion was performed under both acidic (pH 6.3) and basic (pH 8)
conditions, and crystals of identical morphology were obtained
under both conditions. As expected from the previously pub-
lished structure (30), rhMIF in the complex adopts a trimeric
ring architecture. Each monomer is composed of a four-
stranded mixed -sheet and two antiparallel -helices stacked
against the -sheets on the outside of the trimer. In the com-
plex, p425 is found located at the interface of two adjacent
rhMIF trimers (Fig. 4A). Binding of the inhibitor occurs on the
protein surface, mainly through hydrophobic interactions
FIGURE 2. Tautomerase inhibitors block rhMIF binding to CD74-receptor
(A) and the structure of p425 (B). A, inhibition of rhMIF-CD74 interaction by
four tautomerase inhibitors (p425, 1D2, 1H2, and 2F10) identified from HTS.
Biotinylated rhMIF binding to soluble CD74 was detected colorimetrically
(A405) with a streptavidin-alkaline phosphatase conjugate and p-nitrophenyl
phosphate substrate. The most potent confirmed screening hit was p425
with an IC50 of 0.81 M,10-fold higher than that of anti-MIF antibody (anti-
MIF). B, chemical structure of p425 also known as Chicago Sky Blue 6B.
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along one side of the trimer. In the crystal structure, the inhib-
itor also forms highly specific hydrogen bonds with four resi-
dues, Lys32 and Asn110 from one monomer, Glu54 from a sec-
ondmonomer, and Ser53 fromamonomer of an adjacent trimer
(Fig. 4B). These interactions appear to give stability and speci-
ficity to the complex.
To compare themode of binding of p425 with that of HPP or
the active-site inhibitor, coumarin, we compared the co-crystal
structures of the three complexes. Fig. 4, C and D, shows the
superimposition of the co-crystal structures rhMIF-p425 with
rhMIF-HPP (PDB 1CA7 (58)) and rhMIF-coumarin derivative
(PDB 1GCZ (59)), respectively. Structural comparisons
revealed the binding of p425 distal to the active sites and at the
interface of two MIF trimers to be very different from that of
HPP or coumarin. Thus, p425 belongs to a new class of MIF
antagonists that do not engage Pro1 but instead occupy the
interface of MIF trimers.
DISCUSSION
Recognized as a major regulator of inflammation and a cen-
tral upstream mediator of innate immunity, MIF is considered
an attractive therapeutic target for multiple inflammatory and
autoimmune disorders. To date, almost all MIF-directed small
molecule drug discovery efforts have targeted the catalytic tau-
tomerase sitewith themajority of the identified inhibitors func-
tioning by either competing with the substrate or covalently
modifying the catalytic Pro1. Allosteric MIF inhibitors are rare.
With the exception of AV411 and ebselen, no otherMIF inhib-
itors of this class have beendescribed.Herein,we report p425 as
a novel class of allosteric inhibitors that occupies the interface
FIGURE 3. p425 impairs MIF-mediated production of IL-6, IL-8, andMMP-3 and inhibition of p53-dependent apoptosis. A, inhibition of rhMIF-induced
IL-6 (left panel) and IL-8 (right panel) production in human foreskin fibroblast cells in the presence of p425 (white), ISO-1 (stipple), and anti-MIF antibody (black).
IL-6 and IL-8 levels in the culture medium were determined by ELISA, and the percent inhibition was calculated with respect to a no-inhibitor control.
Dose-dependent inhibition of rhMIF-induced IL-6 (B) and IL-8 (C) production in the presence of p425 and ISO-1. D, inhibition of MMP-3 production in the
presence of p425 and ISO-1 in primary human synovial fibroblast cells. MMP-3 levels in the culture medium were determined by ELISA, and the percent
inhibition was calculated with respect to a no-inhibitor control. E, p425 impairs the ability of rhMIF to inhibit p53-dependent apoptosis. HeLa cells were
exposed to camptothecin (CAM) and then treated with rhMIF or rhMIF plus p425. Apoptosis was measured by ELISA. The plot shows the level of apoptosis in
untreated (CAM), treated with rhMIF alone (CAM	MIF) and rhMIF in the presence of 2, 10, and 50 M p425. F, p425 does not cause significant cytotoxicity in
human foreskin fibroblast cells.
Allosteric Inhibition ofMIF
30658 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 36•AUGUST 31, 2012
 at U
niversity of Southern M
ississippi on Septem
ber 15, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of MIF trimers, leading to the loss of its tautomerase, receptor
binding, and pro-inflammatory activities.
The binding of p425 to rhMIF is unique as it engages residues
from two adjacent trimers. p425 forms hydrogen bonds with
Lys32 and Asn110 from one monomer, Glu54 from a second
monomer, and Ser53 froman adjacent trimer. Loss of tautomer-
ase activity could be a direct consequence of p425 bonding with
Lys32 as this residue is important forHPP catalysis. A previously
reported rhMIF/HPP co-crystal structure reveals that Lys32
forms hydrogen bonding with the carboxylate group of HPP
and that during catalysis this interaction is necessary to prop-
erly orient the substrate within the active site (58). In the
rhMIF/p425 complex, Lys32 is likely inaccessible for linkage
with HPP, resulting in inefficient substrate binding. An analo-
gous scenario has been predicted for aryl-1,2,3-triazole deriva-
tives, a set of potent tautomerase inhibitors, which, by molecu-
lar docking studies, were modeled to engage the ammonium
group of Lys32 (60).
Additionally, p425-Lys32 interaction could alter the electro-
static potential of the active site, a feature thought to impact the
tautomerase activity of MIF (61). There are three active sites in
a MIF trimer, and these sites form well defined cavities at the
interface of the monomer subunits (26). Each site contains six
core residues in a unique arrangement, with five residues, Lys32,
Ile64, Tyr95, Asn97, and Val106, surrounding Pro1 (26). In this
hydrophobic environment, Pro1 has an unusually low pKa of
FIGURE 4. Crystallographic analysis of rhMIF-p425 complex. A, ribbon diagram depicting the unique binding of the p425 at the interface of two of the
tightest packed rhMIF crystallographic trimers. The ligand makes contacts with monomer A (blue) and monomer C (cyan) of one trimer and with monomer B
(magenta) of an adjacent trimer. B, ligplot representation of rhMIF-p425 interaction reveals hydrogen bonding (dashed lines) with four residues, Lys32 and
Asn110 fromonemonomer, Glu54 from a secondmonomer, and Ser53 from amonomer of an adjacent trimer. C andD, superimposition of p425-rhMIF complex
with HPP-rhMIF and coumarin derivative-rhMIF, respectively. Arrowheads indicate the respective ligands in the active site.
Allosteric Inhibition ofMIF
AUGUST 31, 2012•VOLUME 287•NUMBER 36 JOURNAL OF BIOLOGICAL CHEMISTRY 30659
 at U
niversity of Southern M
ississippi on Septem
ber 15, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
5.6, a value that is almost 4 pH units lower than the pKa of free
prolines (61). Under physiological conditions, the increased
nucleophilicity of Pro1, due partly to the influence of the posi-
tively charged Lys32, allows it to function as a general base cat-
alyst in the tautomerase reaction (62). It has been suggested
that the role of Pro1 is to provide structural rigidity to the cat-
alytic site to maintain a low pKa micro-environment, and it is
the acidic nature of the active site and not Pro1 per se that is
necessary for catalytic activity (58). Accordingly, structural
alterations in the active site caused by a Pro1 to Gly1 substitu-
tion or spatial shift of Pro1 due to an insertion of an adjacent
alanine, severely impair the catalytic activity (58). In the case of
p425, it is conceivable that hydrogen bonding between the
inhibitor and Lys32 could perturb the spatial orientation of Pro1
and consequently the pKa of the catalytic site, leading to ineffi-
cient or loss of tautomerase activity.
Through a large naphthyl group, p425 also makes contact
withAsn110, a C-terminal residue located farther away from the
active site. Although the role of Asn110 in HPP catalysis is not
well defined, it is possible that the linkage between p425 and
this residue could impair substrate binding. Previous NMR
spectroscopic studies have shown that HPP binding to the
active site affects not only the N terminus but a much larger set
of residues, including Asp102, Gly107, Trp108, Phe113, and Ala114
at the C terminus (63). Truncation of C-terminal residues 110–
114 causes significant structural changes in the active site and
abolishes tautomerase activity, suggesting a possible role for
this region in regulating the conformational flexibility and fine-
tuning the catalytic activity of MIF (63). The large naphthyl
group of p425 in hydrogen bonding with Asn110 could impose
structural rigidity on the MIF trimer rendering it less flexible
and thus impairing proper orientation of the substrate within
the active site.
Our results also show that p425 severely impairs the ability of
rhMIF to bind the purifiedCD74 receptor. BecauseCD74 bind-
ing onMIF occurs in the vicinity of the active site (43), it is likely
that p425 linkage with Lys32, an active-site residue, could
account for the loss in receptor binding. There is evidence that
the binding of substrate or an inhibitor to the tautomerase sites
of MIF induces conformational changes sufficient to impair
antibody recognition (29). In an analogousmanner, binding of a
large molecule such as p425 with Lys32 in the vicinity of the
active site could disrupt the conformational integrity of an
epitope that is critical for receptor binding.
In studies evaluating the pro-inflammatory activities of MIF,
p425 proved to be a much superior inhibitor as compared with
the prototypical MIF inhibitor ISO-1. Our results revealed that
pretreatment of rhMIFwith p425 significantly reduced the abil-
ity of the cytokine to promote secretion of IL-6 and IL-8, pro-
duction ofMMP-3, and inhibition of p53-dependent apoptosis,
as compared with ISO-1 treatment. The mode of binding of
p425 at the interface of two MIF trimers likely accounts for its
enhanced activity as compared with ISO-1, which simply binds
to the catalytic site (64). It has been suggested that inhibitors
that exclusively target the tautomerase site may not be effective
at inhibiting the entire spectrum of MIF-mediated pro-inflam-
matory activities. This is due in part to reports linking several of
the cytokine functions ofMIF to a second catalytic domainwith
a thiol-protein oxidoreductase (TPOR) activity (65). In MIF,
the Cys56-Ala57-Leu58-Cys59 sequence represents the TPOR
consensus motif (CXXC) necessary for the ability of MIF to
catalyze the reduction of insulin and small molecular disulfide
compounds (66–68). The TPOR region also defines part of a
structural epitope recognized by a neutralizing antibody that is
therapeutic in mouse models of sepsis, highlighting the impor-
tance of this region for the in vivo activity of MIF (69). p425
forms hydrogen bondings with Ser53 and Glu54, two residues in
close proximity to the TPOR sequence. This interaction could
likely alter the conformation of the “therapeutic” epitope,
which could account for the enhanced activity of the inhibitor
in assays evaluating the pro-inflammatory function of MIF as
compared with ISO-1. p425 binding to Ser53 and Glu54 could
also impact the chemokine activity of MIF, which orchestrates
cell migration processes, including leukocyte recruitment dur-
ing inflammation (70). The chemokine activity of MIF is medi-
ated through direct binding to chemokine receptors CXCR2
and CXCR4 (70), which on the MIF monomer occurs at an
N-like loop that spans residues 47–56 (71). If the effects of p425
on the oxidoreductase activity of MIF, recognition of neutral-
izing antibodies, and chemokine receptor binding were exper-
imentally confirmed, p425 could define a newway to block both
the catalytic and receptor binding activities ofMIF that result in
a more pronounced therapeutic effect.
In the p425-rhMIF crystal structure, the inhibitor is found
located at the interface of two adjacent trimers. It is not appar-
ent at this point whether p425 inserts into a pocket that forms
between two adjacent rhMIF trimers during crystallization, or
the inhibitor, upon binding to one trimer, brings an adjacent
trimer into close apposition due to its “sticky” nature. Never-
theless, the possibility that p425 could “dimerize” MIF trimers
in solution could prove valuable in studies interrogating possi-
ble roles of MIF oligomerization as a structural basis for the
pleiotropic activities of this cytokine.
MIFwas originally discovered as aT-cell factor that inhibited
the random migration of macrophages and leukocytes (72).
Contrary to its historical and eponymous function, MIF is now
recognized as a keymodulator of innate immunity involved in a
wide range of cellular processes. Neither the molecular mech-
anism nor the structural basis underlying each function of MIF
iswell understood. The tautomerase activity has been the prime
lead in the search to elucidate themolecular basis ofMIF action,
but to date, there are no compelling experimental data linking
enzymatic activities ofMIF with its immunological function. In
fact, the catalytic functions of MIF have been relegated to be
vestigial (1), partly due to lack of bona fide substrates and partly
to the existence of other immune mediators with catalytic
activities of no known biological relevance, such as the adult
T-cell leukemia-derived factor with oxidoreductase activity
(73) and the macrophage-derived factor cyclophilin with
prolyl-peptidyl isomerase activity (74).
MIF is classified as one of five members of the tautomerase
superfamily, a group of structurally related proteins that are
characterized by a -- building block and a catalytic N-ter-
minal proline (Pro1). The other four members of the tautomer-
ase superfamily are bacterial enzymes involved in the degrada-
tion of aromatic hydrocarbons and amino acids (75). Three of
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these enzymes are trimers, and one is a hexamer (a trimer of
homodimers), but all are made up of the same -- structural
unit. Like MIF, the bacterial enzymes can catalyze other reac-
tions in addition to tautomerization. Shared catalytic promis-
cuity in the tautomerase superfamily points to divergent evolu-
tion of these proteins from a common ancestor (75). In the
tautomerase superfamily, it seems nature has fashioned new
activities and structures by “stitching” together various combi-
nations of the same simple structural unit. Still confounding,
however, is how a MIF trimer, made up of three seemingly
simple -- structural units, can modulate such complex
array of biological activities. Recently, the notion that MIFmay
employ different states of oligomerization as amolecular switch
for modulating its various functions has been evoked (28).
Although recombinant MIF purifies as a trimer, native MIF
from bovine brain has been shown to display considerable size
heterogeneity, ranging from 12 to 80 kDa (76). It is conceivable
then that MIF, in different oligomeric states, such as mono-
mers, dimers, trimers or even dimers of trimers, could carry out
distinct functions. Studies to elucidate the structural basis for
the diverse biological activities of MIF could significantly ben-
efit from small molecules that can trap the different oligomeric
species. p425, which bridges twoMIF trimers, could prove cen-
tral to these efforts.
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